Please visit answersincme.com/AXB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Bijal Shah, MD, MS. In this activity, an expert in oncology discusses B-cell acute lymphoblastic leukemia. Upon completion of this activity, participants should be better able to: Describe the rationale for the development of novel dual CD19 x CD3-targeting bispecific antibodies for patients with relapsed/refractory; B-cell acute lymphoblastic leukemia (R/R B-ALL); Discuss the safety profiles of available and emerging CD19 x CD3-targeting bispecific antibodies; and Design treatment plans for patients with R/R B-ALL that optimize the current and future use of CD19 x CD3-targeting bispecific antibodies.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Guidance on Menopause-Related Vasomotor Symptom Management: A Focus on Neurokinin-Targeted Treatment Options
From Evidence to Practice: Where Do BCMA Bispecific Antibodies and Anti-CD38 mAb Combinations Fit Into Community Care for RRMM?
Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma
Management of High-Risk CLL in the BTK Inhibitor Era: Frontline to Double-Refractory Disease
Free AI-powered recaps of CME in Minutes: Education in Oncology & Hematology and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.